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Transplanting Brain Cells Shows Promise for 
Treating Some Causes of Mental Retardation 
Researchers from the University of 
Pennsylvania School of Veterinary 
Medicine a.nd Harvard Medic<:�! School 
have successfully treated in mice brain 
lesions which may c0ntribute to mental 
retardation. The results were published in 
the March 23 issue of the journal Nature. 
The researchers transplanted healthy 
immature brain cells into the brains of 
young diseased mice. As the mice aged, 
the donor cells planted themselves 
throughout the brain, secreted a missing 
enzyme, and appeared as normal 
components oft he central nervous 
system. This resulted in a widespread 
correction of the disease process. This 
strategy was successfully accomplished 
by John H. Wolfe, V.M.D., Ph.D., of the 
School of Veterinary Medicine at the 
University of Pennsylvania in Philadel­
phia, Evans Y. Snyder, M.D .• Ph.D .. of 
Harvard Medical. School and Children's 
Hospital in Boston, and colle<:�gues. 
"The immature brain cells that we 
transplanted Into the diseased brains 
matured into normal brain cells. Appar­
ently, these young cells, whose mature 
form was still undetermined, migrated 
into regions of the brain and developed 
into the appropriate cells of each region," 
said Evan Snyder, of the departments of 
Neurology and Pediatrics at H�rvard and 
Children's Hospital. 
The researchers have been studying 
mice with a disease called 
mucopol ysacchari<.losis type VII. This is 
the animal model for the human disease 
called Sly disease which afflicts fewer 
than 1 in every 100,000 humans. Be­
cause of an inherited deficiency of an 
enzyme called bela glucuronidase, 
substances called glycosaminoglysanas 
accumulate in the brain and other tissues 
where they cause damage that leads to a 
progressive and ultimately fatal degen· 
erative disease accompanied by mental 
retardation. Sly disease belongs to a 
broader group of inherited diseases 
characterized by defects in the break­
down of biomolecu les, and which affect 
approximately 1 in every 1,500 humans. 
To correct this deficiency in mice, the 
researchers 1 ransplanlcd a cell line of 
neural progenitor cells into the cerebral 
ventricles within the brains of the 
newborn mice. By the time the mice 
reached maturity. the donor celts which 
secreted the missing enzyme, had 
engrafted throughout the brain nnd 
appeared as normal constituents of the 
central nervous system, resulting in 
widespread correction of the disease 
Elizabeth R. Moran Honored 
The School honored Elizabeth Ranney Moran during a 
special dinner in May. Shown here are Dean Kelly, Mrs. Moran 
and Mrs. Kelly. Mrs. Moran was presented with the following 
citation: 
In recognition of your generous spirit and great devotion to 
the equine athlete 
Your insight mto the needs of the horse industry, your 
commitme1ll to so many of its worthy causes, and your joy in 
all aspects of the spor1 horse make you, Betty, an inspiration to 
all equine enthusiasts. }'our gracious philanthropic efforts 111 
support of Nevv Bolton Center have left an indelible mark on 
NBC faculty and facilities through the Moran Hearl Station: 
the Surgical Suite and Creme Fraiche Nursing Station,• through 
the Allam Professorship,' and through research, especially in 
sports medicine and comparative orthopedics. The Center and 
all of us personally are indebted to you for your outstanding 
and steadfast leadership and immeasurable kindness in support 
of programs for /he care of horses. 
process. This may be i'l model for treating 
other genetic diseases alft•cting the brain 
or delivering other types of therapeutic 
substance<> to the brain in other types of 
diseases. It i� the first report of using 
these novel vehicles to treat a widespread 
genetic central nervous systum disease. 
Many metabolic diseHses of the 
central nervous system do not respond to 
treatment because the blood-brain barrier 
blocks the entry of dru�s and therapeutic 
molecules in the brain. One way of 
getting around this dilemma is to 
transplant healthy immature nerve cells, 
or "neural progenitor cells" directly into 
the brain. 
1-cven mice with transplanted cells that 
l1ve<.l to an old age showed a dramatic 
absence of pathology in the brain, 
indicating a permanent improvement. 
"Someday we would like to translate 
what we learn from these mice to 
humans, but we still are far away from 
that,·• said John H. Wolfe of the Labora­
tory of Pathology and the Section of 
Medical Genetics at Penn's Veterinary 
School. Jt will entail a better understand­
ing not only of the diseases that cause 
mental retardation, but also the basic 
biology of the immature donor nerve 
cells, cautioned Wolfe and Snyder. 
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